Home > Boards > US Listed > Medical - Healthcare > Gilead Sciences, Inc. (GILD)

#3, Chinese researchers explored patenting one of Gilead's

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
mick Member Profile
Member Level 
Followed By 2,653
Posts 868,171
Boards Moderated 225
Alias Born 09/04/00
160x600 placeholder
Gilead Sciences, Arcus Biosciences Ink 10-Year Partnership Dow Jones News - 5/27/2020 8:07:00 AM
Gilead Sciences & Arcus Biosciences Establish 10-year Partnership to Co-develop & Co-commercialize Next-generation Cancer Imm... Business Wire - 5/27/2020 7:11:00 AM
Location Plays Big Role in Patient Access to First Covid-19 Drug Dow Jones News - 5/22/2020 10:53:00 AM
Correction to the Drug Pricing Article Dow Jones News - 5/21/2020 7:27:00 PM
Coronavirus Revives Debate Over Drug Pricing Dow Jones News - 5/21/2020 2:04:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/20/2020 7:14:33 PM
Gilead, Galapagos: Filgotinib 200mg Achieved Primary Endpoints in Phase 2b/3 Trial Dow Jones News - 5/20/2020 5:08:00 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 5/20/2020 4:03:18 PM
Gilead & Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcer... Business Wire - 5/20/2020 4:03:00 PM
Coronavirus Vaccine Frontrunners Emerge, Rollouts Weighed Dow Jones News - 5/17/2020 5:59:00 AM
Hedge Funds Expect a Cure But Are Wary of Betting Big -- WSJ Dow Jones News - 5/15/2020 3:02:00 AM
Correction to Coronavirus Cure Investing Article Dow Jones News - 5/14/2020 10:36:00 PM
Why Big Investors Aren't Betting It All on a Coronavirus Cure -- 2nd Update Dow Jones News - 5/14/2020 6:14:00 PM
Why Big Investors Aren't Betting It All on a Coronavirus Cure -- Update Dow Jones News - 5/14/2020 4:50:00 PM
Why Big Investors Aren't Betting It All on a Coronavirus Cure Dow Jones News - 5/14/2020 3:05:00 PM
Gilead & Kite Continue to Advance Next Generation Cancer Therapies at 2020 American Society of Clinical Oncology Annual Meeting Business Wire - 5/13/2020 5:00:00 PM
Gilead's Remdesivir Tested With Other Drugs to Fight Covid-19 Dow Jones News - 5/13/2020 5:59:00 AM
Cipla in Licensing Pact With Gilead Sciences for Manufacturing, Distribution of Remdesivir Dow Jones News - 5/13/2020 12:05:00 AM
Mylan Strikes Licensing Deal for Therapy Aimed at Treating Covid-19 Patients Dow Jones News - 5/12/2020 5:12:00 PM
Correction to Jubilant Life Sciences License Article Dow Jones News - 5/12/2020 3:28:00 PM
Jubliant Life Sciences in Non-Exclusive Agreement for Gilead Covid-19 Drug --Reuters Dow Jones News - 5/12/2020 3:12:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2020 12:55:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2020 7:50:48 PM
Health-Care Leaders Question How Remdesivir Is Being Distributed -- 2nd Update Dow Jones News - 5/7/2020 7:44:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/7/2020 7:40:41 PM
mick Member Level  Wednesday, 02/05/20 11:08:40 AM
Re: mick post# 2887
Post # of 3915 
#3, Chinese researchers explored patenting one of Gilead's experimental drugs to combat the novel coronavirus outbreak.

The Foster City, Calif.-based company said it earned $1.7 billion, or $1.30 an adjusted share in the fourth quarter, down from $1.9 billion, or $1.44 a share, a year earlier and short of analysts’ average estimates of $1.67 a share.

Revenue was $5.9 billion, up 1.4% from a year earlier and higher than the $5.71 billion analysts had been expecting.

Affecting the quarter were sales of some of the company’s top-selling drugs, including its HIV medications, which came in at $4.6 billion vs. $4.1 billion a year ago, and sales of its hepatitis C treatments, which fell to $630 million from $738 million in the fourth quarter of 2018.

At the same time, Chinese researchers reportedly have applied for a local patent on an experimental Gilead drug that they believe could help fight the novel coronavirus outbreak - and also significantly bolster Gilead's bottom-line going forward.

The Wuhan Institute of Virology – based in the central Chinese city at the epicenter of the epidemic – has applied for a patent in China for the use of Remdesivir, an antiviral therapy used to treat infectious diseases including Ebola and SARS.

The application was made on Jan. 21 along with a military academy, according to a Feb. 4 statement on the institute’s website.

Beijing has moved aggressively to contain the infection that has killed almost 500 people and infected nearly 25,000. If granted, Gilead will need to get Chinese patent owners on board when it wants to sell the drug for treating the novel coronavirus infection outside China.

Among the U.S. drug companies exploring a potential treatment: AbbVie (ABBV) - Get Report, Johnson & Johnson (JNJ) - Get Report, Moderna (MRNA) - Get Report and Novavax (NVAX) - Get Report.

Shares of Gilead were down 4.41% at $64.43 in morning trading on Wednesday.

TAGSHEALTHCHINASTOCKSPHARMACEUTICALSINVESTINGEARNINGSDRUG APPROVALS
BY M. COREY GOLDMAN
POLITICS
Sanders, Buttigieg Leading Iowa Caucus with Partial Precincts Reporting
BY JACOB SONENSHINE
INVESTING
Coronavirus Could Be Positive Catalyst for Apple App Store
BY TONY OWUSU
INVESTING
Tesla Slides as Coronavirus Delays China Model 3 Deliveries
BY M. COREY GOLDMAN
TAXES
Head of Household: Qualifications, Tax Brackets and Deductions
BY STEVE FIORILLO
INVESTING
Disney+’s Strong Start: What Wall Street’s Saying
BY NELSON WANG
MARKETS
Stocks Rise as Market Rally Extends to a Third Day
BY JOSEPH WOELFEL
INVESTING
Pinterest Receives Buy Rating From Loop Capital Markets
BY DAN WEIL
INVESTING
Ford Shares Tumble After Q4 Profit Miss, Weak 2020 Guidance
BY MARTIN BACCARDAX

SEE MORE
TheStreet
Terms Of Use
Privacy Policy
Advertise
Reprints
Customer Service
Data
Topic Archive
Subscriptions
© 2020 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist